Healthcare Data Platform H1 Defies Investor Trends with $40M Funding Round

Ariel Katz, co-founder and CEO of the nine-year-old healthcare data platform H1, challenges the current investor sentiment towards pre-AI era startups. Katz emphasizes that not all SaaS companies should be generalized, especially those that serve as data providers at their core.

Despite the company's self-interest in this argument, Katz believes that H1's data on physicians globally could be valuable to AI model makers, positioning them as potential customers rather than competitors.

CVS Health Ventures led a $40 million funding round into H1, despite the company already achieving profitability and forecasting over 40% growth this year. H1's previous valuation was $750 million, and the company has focused on profitability and growth through acquisitions, despite the challenging investment landscape for traditional VCs focused on AI startups.